Articles by Dr. Oksana Olkhovyk - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Dr. Oksana Olkhovyk

Dr. Oksana Olkhovyk


Articles
Using Raman Chemical Imaging to Analyze Inhaled Combination Therapies
February 27, 2013

This white paper discusses using Raman Chemical Imaging as method to analyze dry powder formulations containing multiple active ingredients in order to obtain important data about the aerosolization behavior that was previously unavailable. This analysis offers developers new opportunities to optimize the formulations and the delivery devices for combination therapies.

Analysis of Multi-Component Engineered Particles for Inhalation
December 18, 2012

This white paper discusses using Raman Chemical Imaging as method for spatially resolved, chemically-specific analysis of particles that contain multiple active ingredients in order to verify the composition of the particles, which is critical for process optimization, and regulatory requirements. Reviews method used for determining the ratio of drug components.

Analysis of aggregates in nasal spray suspensions.
November 27, 2012

This white paper reviews the importance of measuring particle size distribution and degree of aggregates in nasal spray formulations. Raman chemical imaging is presented as a greatly improved method of analyzing aggregates and agglomerates in nasal spray suspension formulations. Reviews the time and cost savings compared to current practice.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
11%
To select process for new products only
25%
To select processes for both new and legacy products
21%
Do not use QbD
23%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Click here